Status:
COMPLETED
A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664)
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Tumors
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this trial is to determine the effect of food versus a fasted state on single-dose pharmacokinetics of BMS-540215, the active metabolite of Brivanib alaninate
Eligibility Criteria
Inclusion
- For additional information, please contact the BMS oncology clinical trial information service at 855-216-0126 or email MyCancerStudyConnect@emergingmed.com. Please visit www.BMSStudyConnect.com for more information on clinical trial participation.
- Histologic/cytologic diagnosis of advanced or metastatic solid tumors
- ECOG 0-2
- 4/6 weeks since prior therapy
Exclusion
- Brain metastases
- Second primary malignancy
- Thromboembolic disease requiring full anticoagulation within 6 months
- Inability to swallow or absorb oral therapy
Key Trial Info
Start Date :
May 1 2000
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2013
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT00437437
Start Date
May 1 2000
End Date
February 1 2013
Last Update
June 21 2013
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Dana-Farber Harvard Cancer Care
Boston, Massachusetts, United States, 02115
2
Wayne State University
Detroit, Michigan, United States, 48201-2194
3
Duke University Medical Center-Dept Of Medicine
Durham, North Carolina, United States, 27710